Literature DB >> 24381129

SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes).

Ernesto Maddaloni1, Paolo Pozzilli.   

Abstract

Prevalence of type 2 diabetes is increasing worldwide. and management of diabetes is becoming increasingly complex because of the complexity of pathophysiology and the wide therapeutic options. The management of this complexity is difficult because of the different cardiometabolic features of patients. Thus, personalized approaches have been claimed by the most important international societies. Safety, Multifactorial-Approach and reduction of Risk are the three ingredients to get the best Therapy for Diabetes, abbreviated in SMART, as every physician involved in the management of type 2 diabetes should be.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24381129     DOI： 10.1007/s12020-013-0128-3

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


  10 in total

1.  Severe hypoglycemia and risks of vascular events and death.

Authors:  Sophia Zoungas; Anushka Patel; John Chalmers; Bastiaan E de Galan; Qiang Li; Laurent Billot; Mark Woodward; Toshiharu Ninomiya; Bruce Neal; Stephen MacMahon; Diederick E Grobbee; Andre Pascal Kengne; Michel Marre; Simon Heller
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

Review 2.  The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach.

Authors:  Paolo Pozzilli; R David Leslie; Juliana Chan; Ralph De Fronzo; Louis Monnier; Itamar Raz; Stefano Del Prato
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

3.  ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).

Authors:  Lars Rydén; Peter J Grant; Stefan D Anker; Christian Berne; Francesco Cosentino; Nicolas Danchin; Christi Deaton; Javier Escaned; Hans-Peter Hammes; Heikki Huikuri; Michel Marre; Nikolaus Marx; Linda Mellbin; Jan Ostergren; Carlo Patrono; Petar Seferovic; Miguel Sousa Uva; Marja-Riita Taskinen; Michal Tendera; Jaakko Tuomilehto; Paul Valensi; Jose Luis Zamorano; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Guy De Backer; Per Anton Sirnes; Eduardo Alegria Ezquerra; Angelo Avogaro; Lina Badimon; Elena Baranova; Helmut Baumgartner; John Betteridge; Antonio Ceriello; Robert Fagard; Christian Funck-Brentano; Dietrich C Gulba; David Hasdai; Arno W Hoes; John K Kjekshus; Juhani Knuuti; Philippe Kolh; Eli Lev; Christian Mueller; Ludwig Neyses; Peter M Nilsson; Joep Perk; Piotr Ponikowski; Zeljko Reiner; Naveed Sattar; Volker Schächinger; André Scheen; Henrik Schirmer; Anna Strömberg; Svetlana Sudzhaeva; Juan Luis Tamargo; Margus Viigimaa; Charalambos Vlachopoulos; Robert G Xuereb
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

4.  Basal insulin and cardiovascular and other outcomes in dysglycemia.

Authors:  Hertzel C Gerstein; Jackie Bosch; Gilles R Dagenais; Rafael Díaz; Hyejung Jung; Aldo P Maggioni; Janice Pogue; Jeffrey Probstfield; Ambady Ramachandran; Matthew C Riddle; Lars E Rydén; Salim Yusuf
Journal:  N Engl J Med       Date:  2012-06-11       Impact factor: 91.245

5.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Authors:  Paul M Ridker; Aruna Pradhan; Jean G MacFadyen; Peter Libby; Robert J Glynn
Journal:  Lancet       Date:  2012-08-11       Impact factor: 79.321

6.  Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

Authors:  W David Strain; Valentina Lukashevich; Wolfgang Kothny; Marie-José Hoellinger; Päivi Maria Paldánius
Journal:  Lancet       Date:  2013-05-23       Impact factor: 79.321

Review 7.  Medication prescribing in frail older people.

Authors:  Ruth E Hubbard; M Sinead O'Mahony; Kenneth W Woodhouse
Journal:  Eur J Clin Pharmacol       Date:  2012-09-11       Impact factor: 2.953

8.  Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

Authors:  Kausik K Ray; Sreenivasa Rao Kondapally Seshasai; Shanelle Wijesuriya; Rupa Sivakumaran; Sarah Nethercott; David Preiss; Sebhat Erqou; Naveed Sattar
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

Review 9.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

10.  A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

Authors:  Peter C Butler; Michael Elashoff; Robert Elashoff; Edwin A M Gale
Journal:  Diabetes Care       Date:  2013-05-03       Impact factor: 19.112
  10 in total
  12 in total

Review 1.  Combination immunotherapies for type 1 diabetes mellitus.

Authors:  Paolo Pozzilli; Ernesto Maddaloni; Raffaella Buzzetti
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

Review 2.  Lifestyle Management of Diabetes: Implications for the Bone-Vascular Axis.

Authors:  Silvia Pieralice; Francesca Vigevano; Rossella Del Toro; Nicola Napoli; Ernesto Maddaloni
Journal:  Curr Diab Rep       Date:  2018-08-18       Impact factor: 4.810

Review 3.  "H" for Heterogeneity in the Algorithm for Type 2 Diabetes Management.

Authors:  Pieralice Silvia; Zampetti Simona; Maddaloni Ernesto; Buzzetti Raffaella
Journal:  Curr Diab Rep       Date:  2020-03-20       Impact factor: 4.810

Review 4.  Adult-onset autoimmune diabetes: current knowledge and implications for management.

Authors:  Raffaella Buzzetti; Simona Zampetti; Ernesto Maddaloni
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

Review 5.  Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes.

Authors:  Ilaria Cavallari; Alessia Delli Veneri; Ernesto Maddaloni; Rosetta Melfi; Giuseppe Patti; Nicola Napoli; Paolo Pozzilli; Germano Di Sciascio
Journal:  Curr Diab Rep       Date:  2018-10-29       Impact factor: 4.810

Review 6.  Latent Autoimmune Diabetes in Adults: Current Status and New Horizons.

Authors:  Paolo Pozzilli; Silvia Pieralice
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06

Review 7.  Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.

Authors:  Gaia Chiara Mannino; Francesco Andreozzi; Giorgio Sesti
Journal:  Diabetes Metab Res Rev       Date:  2019-01-07       Impact factor: 4.876

8.  Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-Requirement.

Authors:  Ernesto Maddaloni; Nader Lessan; Alia Al Tikriti; Raffaella Buzzetti; Paolo Pozzilli; Maha T Barakat
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

Review 9.  Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs.

Authors:  Giuseppe Patti; Ilaria Cavallari; Felicita Andreotti; Paolo Calabrò; Plinio Cirillo; Gentian Denas; Mattia Galli; Enrica Golia; Ernesto Maddaloni; Rossella Marcucci; Vito Maurizio Parato; Vittorio Pengo; Domenico Prisco; Elisabetta Ricottini; Giulia Renda; Francesca Santilli; Paola Simeone; Raffaele De Caterina
Journal:  Nat Rev Cardiol       Date:  2019-02       Impact factor: 32.419

10.  Glycemic control and risk factors for in-hospital mortality and vascular complications after coronary artery bypass grafting in patients with and without preexisting diabetes.

Authors:  Yanyan Chen; Heng Zhang; Xiaopei Hou; Xiaojue Li; Xin Qian; Xinxing Feng; Shuqian Liu; Na Shi; Wei Zhao; Shengshou Hu; Zhe Zheng; Guangwei Li
Journal:  J Diabetes       Date:  2020-09-14       Impact factor: 4.006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.